All In Biotech

Drug Trial Radar · NCT01379625

Study of Triheptanoin for Treatment of Long-Chain Fatty Acid Oxidation Disorder

Phase 2 Study of Triheptanoin for Treatment of Long-Chain Fatty Acid Oxidation Disorders

Last checked: Nov 20, 2026Latest source record: Mar 23, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

32

Actual

Start

Sep 2011

Primary completion

Apr 2015

Study completion Apr 2015

Sponsor

Lead sponsor
Oregon Health and Science UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
University of Pittsburgh
First posted
Jun 23, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 7 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Humans eat long-chain fat in their diet and use it for energy during exercise and during periods of fasting. Patients with long-chain fatty acid oxidation disorders cannot use dietary fat for energy. They sometimes develop muscle breakdown, and severe pain with exercise or illness. They can also develop a heart that does not function properly. These patients are tired and expend less energy than people who do not have a long-chain fatty acid oxidation disorder. However, they can use a supplement oil called medium chain triglyceride or MCT. This study will determine if a new experimental oil called Triheptanoin can decrease the muscle pain and increase the heart function and the amount of energy in patients with long-chain fatty acid oxidation disorders. Funding source - FDA's OOPD

Conditions

  • Very Long-chain acylCoA Dehydrogenase (VLCAD) Deficiency
  • Carnitine Palmitoyltransferase 2 (CPT2) Deficiency
  • Mitochondrial Trifunctional Protein (TFP) Deficiency
  • Long-chain 3 hydroxyacylCoA Dehydrogenase (LCHAD) Deficiency

Interventions

  • TriheptanoinDrug

    Triglyceride with three heptanoin or 7 carbon fatty acids esterified to a glycerol backbone

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Energy ExpenditureTime frame: change from baseline after 4 months of treatment
  2. Ejection FractionTime frame: 4 months

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Oregon Health & Science University

    Portland, Oregon

  • University of Pittsburgh

    Pittsburgh, Pennsylvania

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.